Pharmaceuticals company Solara Active Pharma Sciences announced Q2FY26 results Q2FY26 Revenue at Rs 3,140 million vs Rs 3,472 million in Q2FY25; down by 10% YoY. Q2FY26 Gross Margin at Rs 1,599 million (51%) vs Rs 1,753 million (50.5%) in Q2FY25 and Rs 1,732 million (54.1%) in Q1FY26. Operating Costs at Rs 1,246 million in Q1FY26 vs Rs 1,138 million in Q2FY25 and Rs 1,157 million in Q1FY26; increased by Rs 108 million YoY. Q2FY26 EBITDA at Rs 352 million (11.3%) vs Rs 615 million (17.7%) in Q2FY25 and Rs 575 million (18%) in Q1FY26. Gross Debt as on 30-Sep-25 at Rs 6,233 million vs Rs 7,760 million at end of FY25; reduced by Rs 1,527 million. Sandeep Rao, MD & CEO, said: "We commenced FY26 with a clear objective: to pivot the business from a phase of reset to one characterized by sustainable, scalable, and reliable growth. Whilst our transformation journey remains intact, our financial performance during this quarter was primarily impacted by short-term disruptions arising from an unscheduled operational shutdown at Mangalore on account of facility upgradation resulting in delayed deliveries and reduced sales volumes during the quarter. While these factors influenced current quarter results, they are transitory. The underlying fundamentals of the business remain strong, supported by a resilient operating model, robust compliance framework, and a diversified portfolio across key markets. Regulated markets and a healthy product mix continue to be a hallmark of the business. We are also actively working to strengthen the balance sheet, aiming to reduce debt through a combination of rights issue and operating leverage, resulting in a lighter and healthier financial position." Result PDF